-
Article
Open AccessNilotinib treatment outcomes in autosomal dominant spinocerebellar ataxia over one year
We evaluated the efficacy and safety of 1-year treatment with nilotinib (Tasigna®) in patients with autosomal dominant spinocerebellar ataxia (ADSCA) and the factors associated with responsiveness. From an instit...
-
Article
Open AccessPopulation pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy
This study aimed to develop a pharmacokinetic (PK) model of oxcarbazepine (OXC) and analyse the relationship between monohydroxylated derivative (MHD), an active metabolite of OXC, and the adverse events of OX...
-
Article
Open AccessHLAs associated with perampanel-induced psychiatric adverse effects in a Korean population
Perampanel (PER) is a new-generation antiepileptic drug that has an occasional but significant shortcoming, psychiatric adverse effects (PAEs). Recently, antiepileptic drug-related adverse reactions, such as s...
-
Article
Open AccessLGI1 expression and human brain asymmetry: insights from patients with LGI1-antibody encephalitis
While brain asymmetry has been a fascinating issue in neuroscience, the critical mechanism remains to be elucidated. Based on some index cases with asymmetric 18F-fluoro-2-deoxy-d-glucose positron emission tomogr...
-
Article
Open AccessHigh albumin level is a predictor of favorable response to immunotherapy in autoimmune encephalitis
There is no known biomarker that predicts the response to immune therapy in autoimmune synaptic encephalitis. Thus, we investigated serum albumin as a prognostic biomarker of early immune therapies in patients...
